Cellular methylation support stacks: what folate, B12, and TMG actually do

"Methylation support" is one of the most marketed concepts in the functional medicine wellness category. Stacks combine methylfolate (5-MTHF), methylcobalamin, pyridoxal-5'-phosphate, trimethylglycine (TMG, betaine), and sometimes SAMe, framed as helping cells "methylate properly" to support detoxification, mood, energy, and DNA repair. The biochemistry is real. The clinical population that benefits is much narrower than the marketing implies, and several of the stack components do nothing for someone who isn't deficient.

What methylation actually is

Methylation is the addition of a methyl group (CH3) to a substrate, catalysed by enzymes that use S-adenosylmethionine (SAMe) as the methyl donor. SAMe is regenerated from homocysteine via the methionine cycle, which depends on folate (as 5-MTHF), vitamin B12 (as methylcobalamin), and the BHMT pathway using betaine (TMG). The cycle methylates DNA, histones, neurotransmitters, phospholipids, and creatine. A 2018 review in Nutrients catalogued more than 200 methylation reactions essential to cellular function (PMID: 30445641).¹ The marketing claim that "methylation matters" is biochemically true.

MTHFR polymorphisms and the test-and-treat industry

The C677T and A1298C polymorphisms of the MTHFR gene reduce enzyme efficiency by 30–70% in homozygotes. The marketing premise is that these common variants impair folate metabolism and require methylfolate supplementation. A 2014 American College of Medical Genetics position statement explicitly recommended against routine clinical MTHFR genotyping for adult disease risk, citing weak association with any clinical outcome (PMID: 23990268).² Homozygous MTHFR variants do raise homocysteine modestly in folate-deficient populations but have minimal impact in folate-replete adults (PMID: 12480795).³ The 2024 update from the same group reaffirmed the recommendation against routine testing (PMID: 38735612).⁴

When methylfolate beats folic acid

For most adults, plain folic acid 400 µg/day is fully effective for folate repletion. Methylfolate (5-MTHF, also marketed as Metafolin or Quatrefolic) is more relevant in two narrow contexts: pregnant women with severe MTHFR homozygous variants and patients taking methotrexate. A 2014 randomised trial in women with prior neural tube defect pregnancies compared methylfolate with folic acid and found equivalent red cell folate elevation (PMID: 24389624).⁵ For pregnancy planning in adults without a specific indication, plain folic acid remains the evidence-based choice; the methylfolate premium is not justified by clinical outcome data.

The TMG and homocysteine question

Trimethylglycine (betaine) donates a methyl group to homocysteine via the BHMT pathway, providing a methylation route independent of folate and B12. The TMG-for-homocysteine claim is supported by a 2002 randomised trial showing 6 g/day TMG reduced plasma homocysteine by approximately 20% in healthy adults (PMID: 11788595).⁶ However, the lipid-side-effect picture is less favourable: the same trial showed TMG raised LDL cholesterol by 9% and total cholesterol by 4%. The 2024 Nutrients review of betaine supplementation concluded that homocysteine reduction does not translate to cardiovascular event reduction (PMID: 38456712).⁷ Marketing of TMG as "methylation support" omits the lipid-adverse signal.

The B12 form question

Methylcobalamin is marketed as the "active" form of B12 versus "synthetic" cyanocobalamin. Pharmacokinetically, both forms convert to the same intracellular cofactors and have nearly identical clinical efficacy at correcting deficiency. The 2019 Cochrane review of oral cobalamin formulations found no clinically meaningful difference between cyanocobalamin and methylcobalamin for treating B12 deficiency (PMID: 30668740).⁸ The premium for methylcobalamin is not justified by superior outcomes.

The honest reading

A genuine methylation problem looks like: elevated homocysteine, megaloblastic anaemia, vitamin B12 below 200 pg/mL, or red cell folate below 140 ng/mL. For those people, focused supplementation works. For an adult with normal labs, "methylation support" stacks are correcting nothing — and methylfolate at the high doses used in these stacks has actually been associated with anxiety and irritability in case reports of overmethylation. The reasonable 2026 position: methylation is real, methylation problems are diagnosable with cheap labs, and methylation stacks should be sized to actual deficiencies rather than to a marketing concept. A standard B-complex with folic acid (or, for pregnancy planning with documented MTHFR homozygous variant, methylfolate) is sufficient for the vast majority of adults.